Quick Answer
Summit Therapeutics Inc. reported Operating Income Loss of -$226.00 million for the year ending 2024.
- Summit Therapeutics Inc. showed an increase of +62.9% in Operating Income Loss from 2023 to 2024.
- This data is from Summit Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2025.
- XBRL data for this metric is available from 2019 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$6.19 million | Q1 2020: -$9.34 million | Q2 2020: -$15.36 million | Q3 2020: -$16.94 million | Q1 2021: -$16.92 million | Q2 2021: -$23.73 million | Q3 2021: -$19.49 million | Q1 2022: -$22.16 million | Q2 2022: -$12.69 million | Q3 2022: -$16.94 million | Q1 2023: -$537.15 million | Q2 2023: -$15.79 million | Q3 2023: -$20.49 million | Q1 2024: -$42.39 million | Q2 2024: -$59.62 million | Q3 2024: -$58.38 million.
- Over the full 7 years of available data (2019 to 2024), Summit Therapeutics Inc.'s Operating Income Loss has declined by 4,293.7%.
- Historical annual values: Fiscal year 2024: -$226.00 million | Fiscal year 2023: -$609.65 million | Fiscal year 2022: -$72.09 million | Fiscal year 2021: -$86.19 million | Fiscal year 2020: -$53.19 million | Fiscal year 2019: -$27.47 million | Fiscal year 2019: $5.39 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: